atamestane has been researched along with Breast Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchett, D; Demers, L; Goss, PE; Langecker, P; Ohorodnik, S; Santen, RJ; Settlage, J; Wang, S | 1 |
| Brodie, A; Goloubeva, O; Macedo, L; Sabnis, GJ; Schayowitz, A; Zhu, Y | 1 |
| Blanchett, D; Bondarenko, IN; Goss, P; Langecker, P; Manikhas, GN; Miller, WH; Pendergrass, KB | 1 |
| Höffken, K | 1 |
1 review(s) available for atamestane and Breast Cancer
| Article | Year |
|---|---|
Experience with aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Forecasting; Humans | 1993 |
2 trial(s) available for atamestane and Breast Cancer
| Article | Year |
|---|---|
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Topics: Androstenedione; Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Estradiol; Female; Gas Chromatography-Mass Spectrometry; Humans; Letrozole; Nitriles; Placebos; Postmenopause; Radioimmunoassay; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazoles | 2007 |
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Topics: Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Steroid; Toremifene; Triazoles | 2007 |
1 other study(ies) available for atamestane and Breast Cancer
| Article | Year |
|---|---|
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
Topics: Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, SCID; Prognosis; Toremifene; Transfection; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |